Jinekolojik Onkolojide Kemoterapi - www.jinekolojivegebelik.com

JİNEKOLOJİK ONKOLOJİDE KEMOTERAPİ

[object Object],[object Object]

[object Object],[object Object],[object Object]

Klinik Kemoterapide Prensipler ,[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object]

Antitümör tedavide faz çalışmaları ,[object Object],[object Object],[object Object],[object Object]

KULLANILAN AJANLAR ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

YAN ETKİLER ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

KEMOTERAPİDE REZİSTAN ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

OVER KANSERİ TERMİNOLOJİ ,[object Object],[object Object],[object Object],[object Object],[object Object]

Erken Evre Epiteliel Over Kanserinde ACT ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Küratif ACT Etkileyen Faktörler ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],BAŞARI BAŞARISIZLIK Frei III E, Clin Cancer Res, 1998

OVER KANSERİ ,[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Obstet Gynecol Clin North Am 1994;21

PLATİNLER ,[object Object],[object Object],[object Object],[object Object],[object Object]

KOMBİNE TEDAVİ ,[object Object],[object Object],[object Object],[object Object],J Natl Cancer Inst 2000;92 GOG; Semin Oncol 1996-23

Paklitaksel (TAXOL ® ) ,[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],Ozols RF, Semin Oncol, 2000

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Gynecol Oncol 2006 Expert Rev anticancer Ther 2005

Tedavi Algoritması Birinci basamak kemoterapi: Karboplatin içeren Platin/Taksan kombinasyon kemoterapisi NÜKS Cb/Taksan içeren primer tedaviden >6 ay sonra nüks Cb/Taksan içeren primer tedaviden sonra ≤6 ay içinde nüks Cb/Taksan kombinasyonu İkinci basamak ajanlar (SALVAJ KEMOTERAPİ)

Salvaj (Kurtarma) Kemoterapi ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SCT Cevap Oranları 18.0 Tamoxifen 24.0 Cisplatin 33.0 Topotecan (Cis Rezistan) 17.0 (Cis Duyarlı) 62.5 Gemsitabin (Cis Rezistan) 27.0 (Cis Duyarlı) 34.0 Oral etoposid (Cis Rezistan) 30.0 Haftalık Taxol Cevap Oranları %

SCT  TAXOL ,[object Object],[object Object],[object Object],[object Object],Lancet Oncol 2002;3

SCT  Etoposid ,[object Object],[object Object],[object Object],[object Object]

SCT  Gemsitabin ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SCT  Topotekan ,[object Object],[object Object],[object Object],[object Object]

Diğer Kombinasyonlar ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

İntraperitoneal Kemoterapi ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Intraperitoneal Kemoterapi Alberts DS, N Engl J Med, 1996 Markman M, J Clin Oncol, 2001 47 36 CR % 53 ay 48 ay 28 ay 22 ay IP Cis+ IV Cb+Taxol IV Cis+Taxol (GOG114) 49 ay 41 ay IP Cis+ IV C IV PC Median OS PFS

Konsolidasyon Kemoterapisi ,[object Object],[object Object],[object Object],Yüksek riskli EOC Cb/Taxol (3 haftada bir, 6 siklus) Cb/Taxol (3 haftada bir, 6 siklus) Taxol 80 mg/m2/hf 24 hafta Takip

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],İmmünokemoterapi

Yeni Non-cytotoxic Ajanlar ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Endometrium CA ,[object Object],[object Object],[object Object],Journal of Clinical Onkoloji 2001, October 15

Endometrium CA’da tedavi rejimleri ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SERVİKS CA ,[object Object],[object Object],[object Object]

VULVA CA ,[object Object],[object Object],[object Object],[object Object]

VAGEN CA ,[object Object],[object Object],[object Object]

GESTASYONEL TROFOBLASTİK NEOPLAZİ ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

TEK AJAN KT ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],Chapman and Hall 1997

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Escobar at al.2001

[object Object],[object Object],[object Object],[object Object],Int J Gynecol Obstet 1998;60

Jinekolojik Onkolojide Kemoterapi - www.jinekolojivegebelik.com

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (16)

Ähnlich wie Jinekolojik Onkolojide Kemoterapi - www.jinekolojivegebelik.com

Ähnlich wie Jinekolojik Onkolojide Kemoterapi - www.jinekolojivegebelik.com (20)

Mehr von jinekolojivegebelik.com

Mehr von jinekolojivegebelik.com (20)

Jinekolojik Onkolojide Kemoterapi - www.jinekolojivegebelik.com